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Abstract
A simple, safe and cost-effective treatment protocol in ovarian stimulation is of great importance in IVF
practice, especially in the case of previous unsuccessful attempts. hCG has been used as a substitute of LH
because of the degree of homology between the two hormones. The main aim of this prospective
randomized study was to determine, for the first time, whether low dose hCG added to rFSH for ovarian
stimulation could produce better results compared to the addition of rLH in women entering IVF-ET,
especially in those women that had previous IVF failures. An additional aim was to find an indicator that
would allow us to follow-up ovarian stimulation and, possibly, modify it in order to achieve a better IVF
outcome; and that indicator may be the cDNA copies of the LH/hCG receptor. Group A patients (n = 58)
were administered hCG and Group B rLH (n = 56) in addition to rFSH in the first days of ovarian
stimulation. The number of follicles and oocytes and, most importantly, implantation and pregnancy rates
were shown to be statistically significantly higher in the hCG group. This study has also determined, for
the first time to our best knowledge, m-RNA for LH/hCG receptors in the lymphocytes of peripheral
blood 40 h before ovum pick-up. cDNA levels of the hCG receptor after ovarian stimulation were
significantly higher among women receiving hCG compared to those receiving LH. In addition, higher levels
were encountered among women with pregnancy compared to those without, although this was not
statistically significant due to the small number of pregnancies. It seems that hCG permits a highly effective
and more stable occupancy of rLH/hCG receptors and gives more follicles and more oocytes. The
determination of cDNA copies could be, in the future, a marker during ovulation induction protocols and
of course a predictor for the outcome of ART in the special subgroup of patients with previous failures.
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Background
The achievement of a simple, safe and cost-effective treat-
ment protocol in controlled ovarian hyperstimulation
(COH) is of paramount importance to improve the qual-
ity of care in assisted reproduction. It is particularly
important in the case of previous unsuccessful attempts.
The midcycle gonadotrophin surge is a major event in the
dynamics of ovulation. Rapidly increasing levels of lutein-
ising hormone (LH) induce a number of key changes in
both oocytes and follicular cells, which further modify the
steroid and protein micro- and macroenvironment. These
physiologic changes have a prominent role in the normal
maturation of oocytes, the process of ovulation, and in
subsequent fertilization and implantation [1].
Human chorionic gonadotrophin (hCG) has been used as
a substitute for the LH surge because of the degree of
homology between the two hormones [2]. hCG has a
slower plasma metabolic clearance, which consists of a
rapid phase in the first 5-9 h following intramuscular (IM)
administration and a slower phase in the first 1-1.3 days
after administration. Both LH and hCG are complex het-
erodimeric glycoproteins with a molecular weight of ~30
K for recombinant human LH (rLH) and 40 K for hCG.
Their carbohydrate molecule is, though, different, thus
leading possibly to a different affinity to the LH/hCG
receptor and therefore to a differentiated function
between LH and hCG. These two hormones have identical
α-subunits and a high cysteine content. Most importantly,
they have the same natural function--to cause ovulation
and support lutein cells. The major differences between
the two hormones include the sequence of the β-subunit,
the regulation of the secretion of the two hormones, the
carbohydrate component and the pharmacokinetics of
clearance of hCG as opposed to LH [3,4].
The LH/hCG receptor has an almost ubiquitous distribu-
tion in reproductive organs, thus suggesting that the
actions of hCG might be more extensive than previously
thought. Independently of follicular stimulation hor-
mone (FSH), low-dose hCG can support development
and maturation of larger ovarian follicles that have
acquired granulosa cell LH/hCG receptors, potentially
providing effective and safer ovulation induction regi-
mens. Human chorionic gonadotrophin seems to be
capable of improving uterine receptivity by enhancing
endometrial quality and stromal fibroblast function. Fur-
thermore, through its actions on insulin-like growth fac-
tor binding protein-1 and vascular endothelial growth
factor, hCG might stimulate endometrial angiogenesis
and growth and extend the implantation window, thus
increasing pregnancy rates [5,6].
Tailoring ovarian stimulation to the individual patient
can be challenging because the ovarian response varies
substantially between patients. Pharmacogenetics has
emerged as a new area of research to improve the balance
between desired and undesired actions of drugs, based
upon the genetic predisposition of the individual patient.
The main aim of this study was to determine whether low
dose hCG added to rFSH in regimens of ovarian stimula-
tion could produce better results compared to the addi-
tion of rLH in women entering IVF-ET, especially in those
women who had previous IVF failures. An additional aim
was to find an indicator that would allow us to follow-up
the ovarian stimulation and, possibly, predict a better IVF
outcome in some women that may lead us to modify this
stimulation; and that indicator may be the cDNA copies
of the LH/hCG receptor.
Methods
Clinical study
This prospective, randomized, pilot study was designed to
compare the IVF outcome between two groups of patients,
the first receiving rLH and the second hCG, both in addi-
tion to rFSH in patients undergoing ovarian stimulation
for IVF-ET. All patients had 2-6 previous failed attempts.
All patients attended our Unit within a period of 12
months. They all were between 36 and 42 years old, had a
body mass index (BMI) of 32 or less, a menstrual cycle
lasting between 21 and 35 days, normal serum levels of
FSH, prolactin and TSH and a normal uterine cavity con-
firmed by hysteroscopy or hysterosalpingography. The
causes for entering the program were: tubal factor, male
factor, mild endometriosis (American Fertility Society
classification stage I or II) [7] or unexplained infertility
(with a history of at least 3 years of infertility). Patients
hadn't had any other treatment with clomiphene citrate or
gonadotrophins for at least 3 months before screening.
Treatment protocol
Group A patients (final n = 58, two cycles were cancelled)
were administered hCG in addition to rFSH in the first
days of ovarian stimulation, while Group B patients (final
n = 56, four cycles were cancelled) were administered rLH
in addition to rFSH. Based on findings by Filicori et al. [8],
the dose of hCG was chosen to be 200 IU IM in Group A
given for four days. The initial dose of rLH was chosen to
be 200 IU based on pharmacokinetic data for LH given for
four days also.
Commercially available GnRH-a (Suprefact, buserelin;
Hoechst, Frankfurt, Germany) was self-administered sub-
cutaneously (sc) into the thigh at a dose of 200 μg/day,
starting on the 2nd day of the menstrual cycle and contin-
uing until 24 h before the administration of hCG. Treat-
ment with rFSH (Gonal-F; Serono, Geneva, Switzerland)
was started on the third day of the menstrual cycle with
200 IU and continued until the administration of hCG for
ovulation induction. rFSH was administered once daily asReproductive Biology and Endocrinology 2009, 7:110 http://www.rbej.com/content/7/1/110
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a sc injection in the abdomen. In Group A patients, 200
IU of hCG were also administered sc for the first five days
of ovarian stimulation. In Group B patients, 200 IU of rLH
were administered sc for the same number of days. The
ovarian response was monitored by ultrasound and meas-
urement of plasma E2 levels, while the dose of rFSH was
adjusted accordingly [9]. The maximum dose allowed was
450 IU/day. The dose was reduced or discontinued if the
patient was at risk of developing OHSS.
Ovulation was induced with 10 000 IU of hCG within 24
h after the last rFSH and GnRH-a administration, prefera-
bly when all of the following criteria had been met: the
largest follicle had reached a mean diameter of at least 18
mm, at least one other follicle had a mean diameter of 16
mm, and serum E2 levels were within an acceptable range
for the number of follicles present. Oocytes were retrieved
by regular follicle aspiration 34-38 h after hCG injection.
From one to three embryos were replaced in the uterine
cavity on day 2 or 3 after OPU.
Luteal phase support
Micronized progesterone (P4) (Utrogestan, Faran, Greece)
(200 mg three times daily) was administered by the vagi-
nal route as luteal phase support, starting after oocyte col-
lection. P4 treatment was continued up to menstruation or
for at least the first 3 weeks if the patient became pregnant.
Definition of pregnancy required a positive βhCG test 14
days after embryo transfer. Definition of a clinical preg-
nancy required an endometrial gestational sac with a
transvaginal ultrasound scan.
At the midluteal phase, careful abdominal ultrasound
assessment was performed to record any signs of OHSS.
The patient then was followed up, and the outcome (preg-
nancy or menstruation) was recorded.
Method of assigning patients to study treatment
The randomization scheme was prepared by a computer
using Proc PLAN in SAS version 6.12 (SAS Institute Inc.,
Cary NC).
Safety evaluation
Safety was assessed through monitoring of all adverse
events that occurred during the study, clinical assessment
of local adverse reactions to injections, a questionnaire on
clinical symptoms associated with OHSS at the time of
hCG injection and at midluteal phase, u/s of the ovaries
and abdomen and monitoring of any pathologic changes
in routine laboratory values.
Statistical methods
Patients were randomly assigned to rLH or hCG treatment
according to balanced blocks of four subjects. Baseline
characteristics of the patients were compared with the t-
test or the Wilcoxon's rank sum test, as appropriate. Com-
parisons of pregnancy and other secondary outcomes
between the two treatments were made by chi-square test
or Wilcoxon's rank sum test, as appropriate. Multivariate
logistic regression analysis was used to identify variables
that are independent predictors of pregnancy outcome.
IRB approval
The study protocol was approved by the Institutional
Review Board or Ethics Committee of Alexandra hospital
before screening the first patient. Written informed con-
sent was asked before study entry, with the understanding
that consent could be withdrawn by the patient at any
time without prejudice.
LH/hCG receptors
I n  t h i s  s t u d y  w e  a l s o  e x a m i n e d  t h e  L H / h C G  r e c e p t o r
mRNA expression in the peripheral blood. The LH/hCG
receptor mRNA expression was determined in the lym-
phocytes of peripheral blood by a novel molecular beacon
based real-time PCR assay (RT-PCR) 40 h before ovum
pick up.
RNA extraction
RNA extraction was performed as previously described
[10]. Briefly, total RNA was extracted from the peripheral
blood by employing a commercially available kit (RNA
blood mini kit; Qiagen, Valencia, CA, USA) according to
manufacturer's instructions. The use of RNase-free DNase
I and carrier RNA, offered highly purified RNA.
Reverse transcription-polymerase chain reaction (RT-
PCR)
Total RNA extracted from peripheral blood was used for c-
DNA synthesis by using Retroscript kit (Ambion, Austin,
TX USA) according to manufacturer's instructions. Reverse
transcription was followed by two rounds of nested PCR
for LH/hCG mRNA and HPRT mRNA. Primer sequences
used in both PCRs for LH/hCG mRNA amplification were
designed with the Primer 3 program [11]. Primers pairs
used for HPRT mRNA amplification have been described
elsewhere [10]. All primers used were ordered from MWG
Biotech (Table 1).
The first round PCR mastermix contained 5 μl c-DNA in a
total 50 μl volume. 5 μl of 10 × PCR buffer, 1.5 mM
MgCl2/l, 0.2 μM of 3' and 5' outer primer, 0.2 mM of each
dNTP/l and 1.5 u Taq polymerase were used (Invitrogen
Life Technologies). Cycling conditions were 94°C dena-
turation, the temperature of annealing specific for primers
and 72°C extension, with each step lasting 1 minute.
Final extraction was performed at 72°C for 10 min. First
PCR products were stored at -20°C.
For the second round of PCR 3 μl of the primary product
were added to 47 μl freshly prepared mastermix contain-
ing PCR buffer, MgCl2, dNTPs, Taq polymerase and innerReproductive Biology and Endocrinology 2009, 7:110 http://www.rbej.com/content/7/1/110
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primers in the same quantities as the first one. The second
round of PCR was performed for 30 cycles in the same
cycling conditions with annealing temperature specific for
inner primers. Products were stored at -20°C.
The amplified products were analyzed by electrophoresis
on 2% agarose gel containing ethidium bromide. 7 μl of
each PCR product run in parallel with a 100 bp DNA lad-
der (Invitrogen Life Technologies). (Figure 1)
The presence of LH/hCG receptor mRNA was investigated
by nested PCR in peripheral blood of women undergoing
IVF-ET. A specific band of 249 bps corresponding to the
LH/hCG receptor was detected in all women examined.
Furthermore the presence of HPRT mRNA in peripheral
blood confirms the integrity of the RT-PCR process.
Real-time PCR
A real-time PCR assay was developed in order to quanti-
tate LH/hCG receptor cDNA which was obtained with a
reverse transcriptase (RT) assay from mRNA extracted
from total blood.
Real-time PCR was optimized for human LH (hLH) recep-
tor cDNA using a set of specific primers (inner set) and a
molecular beacon probe labeled with a fluorescence dye
for the amplification of hLH receptor. More specifically,
hLH receptor primers and molecular beacon were newly
designed targeting at a conserved region of gene sequence.
The design of the primers and the molecular beacons was
according to the standard requirements such as: (1) to
avoid primer-beacon and primer-dimers and (2) the melt-
ing temperatures (Tm) of the primers must be similar and
at least 5-10°C lower than Tms of the molecular beacons.
The software tool used for the assessment of the Tm calcu-
lations was from the Virtual Genome Centre http://
alces.med.umn.edu/VGC.html. The reaction mixture for
RLT-PCR contained 2 μl LightCycler FastStart Taq Reac-
tion Mix 10× (Roche, Molecular Biochemicals, Man-
nheim, Germany), 6 mM MgCl2, 0.75 μM primer hCG_for
inner (forward) 5'-GAACTGAGTGGCTGGACTA-3', 0.75
μM primer hCG_rev inner (reverse) (Table 1), 5'-
GCAAAAGTCTGCAAAGGAGA-3', 0.017 μM hLH_beacon
5'-GCCGGC  CTGCTTACCCAAGACACCCCGATGTGCT
GCCGGC-3' labeled with fluoresceine at the 5'-terminus
and at their 3'-terminus bonded BHQ1, which is the
quencher (Black Hole quencher 1). (MWG-BIOTECH Inc,
U.K) (bold text indicates the complementary sequences
forming the hairpin structure), 1.5 U FastStart Taq DNA
polymerase (Roche, Molecular Biochemicals, Mannheim,
Germany) and 1 U of uracil-DNA glycosylase (Roche,
Molecular Biochemicals, Mannheim, Germany) in a final
volume reaction 20 μl. Ten microliters of DNA sample
DNA were added in the LightCycler 2.0 capillaries con-
taining 10 μl of the reaction mix. The amplification con-
ditions were optimized for LightCycler I as follows: one
cycle of denaturation: 95°C for 10 min followed by 50
cycles of amplification at: 95°C for 10 s, 55°C for 10 s and
at 72°C for 10 s. Uracil-DNA glycosylase was used to elim-
inate PCR 'carry over' contaminations from previous PCR
reactions. The cycle number during which the fluores-
Table 1: PCR Primers
mRNA PCR primer
pair
Primers
5'-3'
Sequence Annealing
Temperature
(°C)
Product
size
LH/hCG Outer pair Forward CAA TGT GAA AGC ACA GTA AGG A 56
Reverse AGG CTA TGA GCA GCA GAT AGA G 56 343
Inner pair Forward GAA CTG AGT GGC TGG GAC TA 56
Reverse GCA AAA GTC TGC AAA GGA GA 56 249
HPRT Outer pair Forward CTCCGCCTCCTCCTCTGCT 50
Reverse GCCTGACCAAGGAAAGCAAAG 50 528
Forward GCCGGCTCCGTTATGGCG 55
Inner pair Reverse AGCCCCCCTTGAGCACACAGA 55 226
Gel electrophoresis of RT-PCR products for hCG-R (frag- ment 249) in peripheral blood of women undergoing IVF-ET Figure 1
Gel electrophoresis of RT-PCR products for hCG-R 
(fragment 249) in peripheral blood of women under-
going IVF-ET. No 1 sample = positive control (cumulus 
cells), No 2 sample = negative control (distilled water), No 3-
6 samples = peripheral blood of women undergoing IVF-ET.
249 bp 
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cence signal is above the background (CT) is proportional
to the initial log concentration of the target DNA. For each
run a standard curves was created in a 6-log range by 1:10
serial dilutions of hCG receptor's standard. The slope and
correlation coefficient of each standard curve were calcu-
lated based on the average threshold cycle (CT) values
measured in eight replicates for each dilution point rang-
ing from 106 to 101 standard DNA templates. The PCR
efficiency, E, corresponding to the experimentally derived
dynamic range was computed as (10-1/s - 1) 100, where s
is the slope of the standard curve generated. The concen-
tration of hCG receptor at unknown extracted DNA sam-
ples quantified using the standard curve for external
standard ds and was expressed as copies per μl of cDNA.
Preparation of standard DNA
hCG receptor amplicons were used as external standards
after quantification in LightCycler 2.0 (Roche, Molecular
Biochemicals, Mannheim, Germany) using PicoGreen
dsDNA Quantification Kit (Molecular Probes). The con-
centration of hCG receptor amplicons was estimated
according to standard curve calculated for serial dilutions
of genomic DNA of known concentration (250-6.25 ng);
Tenfold serial dilutions of the standards DNA with known
DNA copy number were used for the generation of stand-
ard curves in amplification assays using molecular-bea-
con-based real-time PCR.
Results
This randomized, pilot clinical study was performed in a
study period of 12 months between January 2007 and
December 2007. A total of 120 patients were enrolled and
randomized. Six women did not complete the study; two
presented at risk for OHSS and four failed to develop a fol-
licle with a mean diameter of at least 17 mm. Of the
remaining 114 women, 58 belonged to Group A (received
hCG) and 56 to Group B (received rLH). All had at least
one embryo transferred and all completed the midluteal
phase assessment. The luteal phase was monitored in all
patients who received hCG treatment.
The patients' characteristics prior to entering the program
are summarized in Table 2. These characteristics did not
differ between the two groups. The mean (SD) age of the
patients was 36.4 (4.2) and 37.3 (1.8) for the hCG and LH
group respectively (p = 0.147). BMI was similar in the two
groups (mean (SD): 22.7 (3.0) and 23.7 (3.4) for hCG
and LH respectively, p = 0.129). Mean (SD) serum FSH
was 8.4 (3.1) IU/L for the hCG group and 8.2 (2.8) IU/L
for the LH group, mean (SD) serum LH was 6.1 (2.1) and
6.4 (3.0) IU/L respectively and mean (SD) PRL was 12.2
(6.2) and 10.3 (4.7) ng/ml respectively for the two
groups. The cause and duration of infertility, as well as the
history of previous assisted reproductive techniques
(ART) and non-ART pregnancies, were similar between
the treatment groups. Uterine and ovarian sizes were com-
parable between the two groups (data not shown).
The IVF outcome in the two groups is presented in Table
3. The mean (SD) number of days of ovarian stimulation
was 10.8 (1.9) days for the hCG group and 11.1 (1.2) for
the rLH group (p = 0.240). The mean (SD) total rFSH dose
per patient was 2940 (1231) IU (hCG treatment) and
4261 (1090) IU (rLH group) (p < 0.001). Median (25th,
75th) serum E2 was 1888 (1119, 2118) and 720 (530,
1825) pg/ml for the hCG and LH group, respectively (p =
0.003).
Oocyte retrieval, fertilization and embryo cleavage
The median number of follicles was 7.0 for hCG and 4 for
LH (p < 0.001) and the median number of oocytes
retrieved per group was 6 for the hCG group and 3 for the
LH one (p < 0.001). No patient had more than 14 oocytes.
The majority of oocytes were in metaphase II (75.0% for
the hCG group and 66.7% for the rLH group, p = 0.752.
The percentage of nuclear maturity was thus comparable
between rLH and hCG
There was no significant difference in fertilization rate
between the two treatment groups (71.4% for hCG vs.
66.7% for LH, p = 0.317).
Table 2: Baseline characteristics of patients according to treatment group
hCG (N = 58) LH (N = 56) P
Age (years), mean (SD) 36.4 (4.2) 37.3 (1.8) 0.147
BMI (kg/m2), mean (SD) 22.7 (3.0) 23.7 (3.4) 0.129
FSH (IU/L), mean (SD) 8.4 (3.1) 8.2 (2.8) 0.683
LH (IU/L), mean (SD) 6.1 (2.1) 6.4 (3.0) 0.623
PRL (ng/ml), mean (SD) 12.2 (6.2) 10.3 (4.7) 0.071
Years of Infertility (years), mean (SD) 6.7 (2.3) 6.9 (2.8) 0.677
Cause of infertility, %
Tubal Factor 60 52 0.399
Male Factor 37 39
Other 3 9Reproductive Biology and Endocrinology 2009, 7:110 http://www.rbej.com/content/7/1/110
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The median number of transferable embryos was 4 for the
hCG group and 2 for the rLH group (p < 0.001).
The mean number of embryos transferred was 2.4 ± 0.4
for the hCG group and 2.5 ± 0.4 for the LH group (p =
0.185) (Table 3).
Only embryos transferred during the study treatment
cycle were considered in this analysis. All 114 patients had
at least one embryo transferred. No more than three
embryos were replaced in any patient.
Endometrium
The percentage of patients with endometrial thickness > 8
mm was slightly higher in the hCG group (80% compared
to 69%; p = 0.190).
Implantation rate
Implantation rate (i.e. total pregnancies over the total
number of transferred embryos) was 8.9% for the hCG
group and 4.4% for the rLH group p = 0.125 (Table 3). No
monozygotic were found in this study.
Pregnancy rate
In a univariate analysis, we assessed the effect of parame-
ters such as age, BMI, basal serum hormone values and
treatment with either hCG or LH on the achievement of
pregnancy (Table 4). Treatment with hCG was found to be
the only parameter that significantly increases pregnancy
outcome expectation. A total of 16 clinical pregnancies
(27.6%) were recorded for hCG patients while 6 pregnan-
cies (10.7%) were recorded for the rLH group (p = 0.022)
(Table 4).
We also observe that (Table 5), after having adjusted for
potential differences in age, BMI and baseline PRL, FSH,
E2, women receiving hCG treatment have 3.6 times
higher probability of achieving pregnancy compared with
women receiving LH (95% CI: 1.21-10.71, p = 0.022).
Ovarian hyperstimulation syndrome and adverse events
The proportion of patients presenting with moderate
OHSS [12] was similar in the two groups (about 12%)
and no serious adverse events were noted in any group.
cDNA copies of the hCG receptor
cDNA levels after ovarian stimulation were significantly
higher among women receiving hCG compared to
women receiving LH (median levels: 25.3 copier per μl of
cDNA vs 6.8 copier per μl of cDNA, respectively, p =
0.012) (Table 6).
As far as prediction of pregnancy outcome by cDNA levels
alone, higher levels are encountered among women with
Table 3: Impact of treatment on intermediate outcomes
hCG LH P
Duration of stimulation (days)
mean (SD)
10.8
(1.9)
11.1
(1.2)
0.240
E2 on the day of hCG (pg/ml)
median (25th - 75th percentile)
1888
(1119, 2118)
720
(530, 1825)
0.003
Total rFSH dose/patient
mean (SD)
2940
(1231)
4261
(1090)
<0.001
Number of follicles
median (25th - 75th percentile)
7
(5,9)
4
(3,7)
<0.001
Oocytes number
median (25th - 75th percentile)
6
(4,7)
3
(2,6)
<0.001
Proportion of mature oocytes (%)
median (25th - 75th percentile)
75.0
(57.1,100)
66.7
(66.7,100)
0.752
Proportion of fertilized oocytes (%)
median (25th - 75th percentile)
71.4
(66.7, 80.0)
66.7
(50.0,100)
0.317
Number of transferable embryos
median (25th - 75th percentile)
4
(2,4)
2
(1,3)
<0.001
Proportion of patients with endometrium thickness >8 mm (%) 80 69 0.190
Implantation rate (%) 8.9 4.4 0.125
Table 4: Univariate associations of patients' characteristics and 
treatment with pregnancy outcome
Pregnancy
Yes No P
Age, mean (SD) 36.6 (3.3) 36.9 (3.3) 0.736
BMI, mean (SD) 23.1 (3.8) 23.2 (3.1) 0.934
FSH, mean (SD) 7.28 (2.98) 8.55 (2.93) 0.071
PRL (SD) 11.9 (5.2) 11.1 (5.6) 0.551
LH (SD) 6.29 (2.53) 6.24 (2.60) 0.944
Treatment, n (%)
hCG 16 (27.6) 42(72.4) 0.022
LH 6 (10.7) 50 (89.3)Reproductive Biology and Endocrinology 2009, 7:110 http://www.rbej.com/content/7/1/110
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pregnancy compared to those without, this is not statisti-
cally significant though (Table 6).
Discussion
The necessary and the optimal dose as well as the time of
LH administration in IVF cycles for the achievement of
good quality oocytes and embryos has not yet been deter-
mined. The two-cell theory suggests that both FSH and LH
are needed for normal follicular growth and maturation,
but until now the main role has been attributed to FSH.
Studies in non-human primates have revealed that LH
may act by increasing intraovarian androgens which pro-
mote FSH responsive granulosa cell function [8,13] and,
previous studies in humans have shown that LH acts syn-
ergistically with FSH to promote follicular growth [14].
However, no data exist on the potential clinical benefit of
an "LH priming" effect as well as hCG.
Several studies have demonstrated that the administration
of LH activity combined with FSH can exert significant
actions on folliculogenesis. Still, reports on clinical data
have been controversial. Late reports have employed rLH
either before the administration of rFSH [6] or during the
late part of ovarian stimulation [8,15,16]. A beneficial
induction effect has been shown when rLH is adminis-
tered before rFSH commenced in IVF cycles [6] but the
authors suggested that the effect of supplementation with
rLH on the clinical outcome needs to be clarified in the
future. Our previous data with human luteinising hor-
mone supplementation in the beginning of ovarian stim-
ulation showed a beneficiary effect [17] and this effect is
with the early addition of hCG in this study.
The action of LH in preantral and small antral follicles was
reported in literature to be limited [18]. However, granu-
losa cells express LH/hCG receptors and can be stimulated
by both FSH and LH [19]. It has also been demonstrated
by us that mRNA for the FSH and LH receptors exists in
denuded oocytes as well as in preimplantation embryos at
different stages, indicating a physiological role of LH in
the oocyte maturation process and early embryonic devel-
opment in the mouse and in humans [10,11]. Indeed,
luteinising hormone activity can be provided in various
ways: by human-derived LH contained in hMG, by recom-
binant LH, and by human-derived or recombinant hCG.
Our study has shown, for the first time to our best knowl-
edge, that the administration of 200 IU of hCG daily, in
addition to rFSH, is a safe and possibly better alternative
of human recombinant luteinising hormone supplemen-
tation for patients undergoing IVF/ICSI-ET. As stated
before, other investigators have already used 200 IU of
hCG in the last 3-4 days of ovarian stimulation in the long
protocol [8,15,16]. In our study we used hCG supplemen-
tation during the first five days of ovarian stimulation in
the short protocol. No negative impact of low-dose hCG
administration was detected in patients receiving this
treatment.
We also have to note that if we analyse the results with
intention to treat, that is including the cases of patients
that dropped treatment, we still have a statistically signif-
icant difference between pregnancy rates (p = 0.018).
In most of the currently used ovarian stimulation proto-
cols, serum LH is clearly suppressed through pituitary
down regulation by GnRH agonists or antagonists. In the
short protocol, LH is suppressed during the final days of
the follicular growth (days 7-11). It seems, from our
study, that the administration of 200 IU of hCG daily
from days 3- 7 during the follicular growth permits a suf-
ficient LH level in this period of ovulation induction. Our
results have shown that with hCG we had lower number
of gonadotrophin ampoules used, higher fertilization
rate, higher and a better pregnancy rate with a tendency
for a better implantation rate. In addition, the percentage
of mature oocytes and the number and quality of embryos
was comparable between rLH and hCG, thus showing that
hCG, in the specific dose and way of administration, had
no harmful effect on ovarian stimulation.
An explanation of the better ovulation profile in hCG
treatment cycles could be the different isoform of hCG as
compared to rLH. Differences in the carbohydrate moiety
may make the molecule more sensitive to the binding
Table 5: Multiple logistic regression model for potential factors 
associated with increased probability of pregnancy
Odds ratio 95% CI P
Age (/year) 1.03 (0.00, 1.20) 0.735
BMI 1.02 (0.87, 1.19) 0.849
Therapy hCG/LH 3.60 (1.21, 10.71) 0.022
PRL 1.01 (0.92, 1.11) 0.865
FSH 0.84 (0.70, 1.02) 0.078
E2 1.00 (1.00, 1.00) 0.746
Table 6: cDNA levels according to treatment and pregnancy 
outcome
cDNA (copies/μl)
median (25th - 75th percentile)
P
Treatment, n(%)
hCG 25.3 (4.5,126.0) 0.012
LH 6.8 (1.4, 48.5)
Pregnancy, n(%)
Yes 14.2 (4.5, 72.9) 0.687
No 9.0 (2.6, 92.9)Reproductive Biology and Endocrinology 2009, 7:110 http://www.rbej.com/content/7/1/110
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receptor. In addition, the longer plasma half-life of hCG
(half life of hCG is 33 hours while half life of rLH is 10-12
hours) results to a better and prolonged effect in the ovar-
ian stimulation process [3,20]. It seems, therefore, that its
longer plasma half-life and its greater potency (roughly six
to eight times greater than that of LH) permit highly effec-
tive and more stable occupancy of the LH\hCG receptors.
The fact that serum E2 levels in patients who received rLH
were statistically significantly lower than in patients
treated with hCG, shows that indeed the occupation of
the LH/hCG receptor in the rLH-administered patients is
less compared to the hCG stimulated patients.
The fact that single doses of rLH have a shorter effect than
those of hCG is further substantiated by the performance
of rLH in relation to the main characteristics of a natural
LH surge as reported in the literature. The natural surge
lasts for about 2 days (49 ± 9 h) and is composed of an
ascending phase (around 14 h), a plateau (around 14 h),
and a descending phase (around 20 h) [21]. LH serum lev-
els, when measured by RIA, are about 10-20 times the
basal LH levels. The surge profile obtained after a single
injection of 5,000 IU hCG is very different from that of the
natural LH surge. The main differences are the total dura-
tion (the hCG surge can last up to 120 h) and the length
of the descending phase. Previous publication suggested
that using a conversion factor of 2.5, a dose of 12,500 IU
rLH would be as effective as 5,000 IU hCG in humans
[22].
In terms of safety, this study shows that 200 IU of hCG is
a well tolerated dose. Reported adverse effects are similar
to those usually reported during stimulation cycles with
rFSH and hMG. No negative impact of low-dose hCG
administration was detected in patients receiving this
treatment. Our study, thus, demonstrated that the admin-
istration of 200 IU of hCG daily can be applied as a sup-
plement in patients with previous failed attempts during
the short protocol in the first 5 days of superovulation.
This study has also determined, for the first time to our
best knowledge, m-RNA for LH/hCG receptors in the lym-
phocytes of peripheral blood 40 h before ovum pick up.
cDNA levels of the hCG receptor after ovarian stimulation
were significantly higher among women receiving hCG
compared to women receiving LH. In addition, higher lev-
els were encountered among women with pregnancy
compared to those without, although this was not statisti-
cally significant due to the small number of pregnancies.
It seems that hCG permits a highly effective and more sta-
ble occupancy of rLH/hCG receptors and gives more folli-
cles and more oocytes. This is due to the "down
regulation" mechanism that is caused by the effect of the
hormone on the receptors. As far as hCG and rLH are con-
cerned for ovarian simulation, from this pilot study, it
seems that the addition of hCG in the short protocol helps
to improve the ovulation profile. It remains to be clarified,
with the successive measurements of hormone in the
blood during ovulation induction, which range of hCG in
the blood relates with the optimum number of receptors.
The LH/hCG receptor has an almost ubiquitous distribu-
tion in reproductive organs, thus suggesting that the
actions of hCG might be more extensive than previously
considered [22,23]. The localization of the LH/hCG
receptors in extragonadal reproductive tissues has sug-
gested that hCG might exert additional actions and that
these mechanisms could be exploited to enhance the effi-
cacy of treatment used to manage infertile patients. The
expression of LH/hCG receptors by theca cells and by
granulosa cells has been well characterized [23,24]. Low-
dose hCG can also be used instead of LH to permit in a
more sustained manner the progression of folliculogene-
sis [5]. Moreover, the tendency, although not statistically
significant for this sample number, for better implanta-
tion rate noted with hCG may reflect a more beneficial
action to the endometrium compared to that of rLH
administration since the number of embryos and their
quality was the same.
However, the importance of this factor for the moment is
not clearly established. The cDNA copies of LH/hCG
receptor may act in concert with other environmental and
genetic factors that could contribute to improve the ovu-
lation protocols in the future. Also the determination of
cDNA copies could be, in the future, a marker during ovu-
lation induction protocols and of course a predictor for
the outcome of ART in special subgroup of patients with
previous failures. We are currently determining the varia-
tion of cDNA copies from the start of ovarian stimulation
till luteal phase to see if there is a correlation between
their level throughout ovarian stimulation and pregnancy
outcome and if stimulation can be adjusted accordingly in
order to provide a better outcome.
Finally, the results in this study are in agreement with the
conclusion published recently by Filicori et al [5] stating
that greater understanding of the physiologic role that
hCG might play in human reproduction is beginning to
suggest novel therapeutic applications for this traditional
hormone of pregnancy.
Conclusion
Our study, as stated previously, demonstrated that the
administration of 200 IU of hCG daily can be applied in
addition to rFSH in patients with previous failed attempts
during the short protocol in the first 5 days of superovula-
tion increasing, thus, pregnancy rate.
This study has also determined, for the first time to our
best knowledge, m-RNA for LH/hCG receptors in the lym-
phocytes of peripheral blood 40 h before ovum pick up.Publish with BioMed Central    and   every 
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cDNA levels of the hCG receptor after ovarian stimulation
were significantly higher among women receiving hCG
compared to women receiving LH. In addition, higher lev-
els were encountered among women with pregnancy
compared to those without, although this was not statisti-
cally significant due to the small number of pregnancies.
The determination of cDNA copies could be, in the future,
a marker during ovulation induction protocols and of
course a predictor for the outcome of ART in special sub-
group of patients with previous failures.
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